Lindsey Shapiro, PhD,  science writer—

Glitches in a cellular process that are often seen in neurodegenerative diseases and dementia may also play a role in pancreatic cancer development, a…

A cell-based immunotherapy that’s designed to overcome the defense mechanisms that help ovarian cancer evade treatment was highly effective at killing cancer cells in preclinical…

The European Union (EU) expanded its approval of Sarclisa (isatuximab-irfc), making it available to newly diagnosed adults with multiple myeloma who are eligible for…

A vaccine therapy called ELI-002 2P led to anti-cancer immune responses in a Phase 1 trial and showed potential for preventing disease relapses among people…

The number of uterine cancer cases and related deaths — the disease’s incidence and mortality rates — in the U.S. are expected to substantially rise…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to…

Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…

The first patient has been dosed in a Phase 3 trial testing the investigational therapy BAT8006 in people with platinum-resistant ovarian cancer, according to the…

A European Medicines Agency committee has recommended that Sarclisa (isatuximab), used in combination with standard-of-care medications, be approved for the treatment of adults newly…

Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…